Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74158 | 0.85 | ADRB2 (0.51) | ADRB2ADRB1THRB | |
| SCHEMBL5252625 | 0.81 | ADRB2 (0.44) | ADRB2ADRB1ALDH1A1HTR1A | |
| SCHEMBL13676818 | 0.81 | ADRB2 (0.47) | ADRB2ADRB1MAPTHTR1A | |
| SCHEMBL5247549 | 0.81 | L3MBTL1 (0.53) | ADRB2ADRB1ALDH1A1MAPTTHRB | |
| SCHEMBL8036410 | 0.79 | ADRB2 (0.49) | ADRB2ADRB1ALDH1A1HTR1A | |
| SCHEMBL8036408 | 0.79 | ADRB2 (0.46) | ADRB2ADRB1 | |
| SCHEMBL20739974 | 0.79 | ADRB2 (0.46) | ADRB2ADRB1ALDH1A1HTR1A | |
| SCHEMBL5250163 | 0.79 | TAAR1 (0.58) | — | |
| SCHEMBL12394754 | 0.77 | GABRA1 (0.45) | ADRB2ADRB1ALDH1A1MAPTTHRB | |
| SCHEMBL10701443 | 0.77 | L3MBTL1 (0.56) | ADRB2ADRB1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1369405-B1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL CO (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-6861566-B2 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1369405-A1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | CYP1B1, CBR1, CYP1A1 | ADRB2 45/4885ADRB1 32/4885ALDH1A1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.